Abstract
Peripheral-type benzodiazephine receptors (PBR) are involved in steroidogenesis and are sensitive to stress. Reduced platelet PBR density has been demonstrated in generalized anxiety disorder (GAD), but not in obsessive-compulsive disorder (OCD). We extended this observation to another anxiety disorder, namely, posttraumatic stress disorder (PTSD). Eighteen post-Persian Gulf War PTSD patients and 17 age- and sex-matched controls were included in the study. All subjects were evaluated using the Structured Clinical Interview for DSM-III-R-Patient Version. The severity of symptoms was assessed using the DSM-III-R scale for PTSD, the Impact of Event Scale, the Beck Depression Inventory, and the State-Trait Anxiety Inventory. [3H]PK 11195 was used to label platelet PBR. All psychological parameters (except trait anxiety) were higher in PTSD patients compared to controls. Decreased platelet PBR density (−62%; p <. 001) was observed in the PTSD patients compared to controls. The reduction in PBR observed in PTSD patients was in accordance with the findings in GAD patients, but differed from those obtained in OCD patients. It is possible that the receptoral downregulation is an adaptive response aimed at preventing chronic overproduction of glucocorticoids in hyperarousal states.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gavish, M., Laor, N., Bidder, M. et al. Altered Platelet Peripheral-Type Benzodiazepine Receptor in Posttraumatic Stress Disorder. Neuropsychopharmacol 14, 181–186 (1996). https://doi.org/10.1016/0893-133X(95)00078-R
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/0893-133X(95)00078-R
Keywords
This article is cited by
-
Translocator protein (18kDa) TSPO: a new diagnostic or therapeutic target for stress-related disorders?
Molecular Psychiatry (2022)
-
Translocator protein 18 kDa: a potential therapeutic biomarker for post traumatic stress disorder
Metabolic Brain Disease (2020)
-
Antidepressant-Like and Anxiolytic-Like Effects of ZBD-2, a Novel Ligand for the Translocator Protein (18 kDa)
NeuroMolecular Medicine (2017)
-
Translocator protein (18 kDa) (TSPO) as a therapeutic target for anxiety and neurologic disorders
European Archives of Psychiatry and Clinical Neuroscience (2012)
-
Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders
Nature Reviews Drug Discovery (2010)